
Shenzhen Huayuan Regenerative Medicine
Bio-artificial organs addressing chronic kidney and pancreas disease.
Date | Investors | Amount | Round |
---|---|---|---|
investor | €0.0 | round | |
investor investor investor | €0.0 | round | |
* | CNY20.0m | Seed | |
Total Funding | 000k |
Shenzhen Huayuan Regenerative Medicine, founded in 2018, is a research and development company creating bio-artificial organs to address organ shortages. The firm leverages human-derived stem cell and tissue engineering technologies to develop products for patients with kidney disease and diabetes, with a key focus on creating an implantable bio-artificial kidney and pancreas. The company's primary strategy is to develop a portfolio of therapies for kidney disease, including stem cells, exosomes, and drugs, alongside its main goal of manufacturing transplantable organs.
The founding team includes experts in cell and tissue engineering, clinical professors, and former executives from major pharmaceutical companies. The company is led by CEO Zheng Lixin and Legal Representative Li Jùn. Huayuan Regenerative Medicine operates a GMP-level cell and bio-tissue engineering center at its headquarters in Shenzhen, with additional labs in Guangzhou, Wuhan, Hangzhou, and Hong Kong, forming one of Asia's larger bio-artificial organ R&D teams. The company collaborates with several domestic universities and hospitals to advance its research. Its research personnel, accounting for over 60% of its more than 90 employees, hold degrees from institutions such as Harvard University, Kyoto University, and the University of Toronto.
The company has secured multiple rounds of financing, including a Pre-A round led by Sequoia China Seed Fund in July 2021 and a Pre-A+ round worth tens of millions of RMB in January 2023, led by Efung Capital. This capital is being used to advance large animal experiments, initiate researcher-led clinical trials, and prepare for Investigational New Drug (IND) submissions. Huayuan Regenerative Medicine has submitted 85 patent applications, with 43 granted. It has received numerous accolades, including winning the Shenzhen Innovation and Entrepreneurship Competition in 2019 and the Alibaba-Hong Kong JUMPSTARTER Global Entrepreneurship Competition in the life sciences category in 2020.
Keywords: regenerative medicine, bio-artificial organs, tissue engineering, stem cell technology, artificial kidney, artificial pancreas, kidney disease, diabetes treatment, organ transplantation, cell therapy, organoids, IND submission, clinical trials, GMP manufacturing, life sciences R&D